BrainXell Unveils Innovative Human Neurons for Pain Research

BrainXell, a biotechnology company based in Madison, Wisconsin, has introduced its new human induced pluripotent stem cell (iPSC)-derived sensory neurons. This innovative cellular platform aims to enhance research in pain biology, sensory transduction, and ion channel pharmacology. The launch, announced on March 4, 2026, promises to provide researchers with a more robust and reproducible model for studying complex human sensory neuron functions.

These sensory neurons exhibit significant expression of key genes and proteins associated with sensory neuron functionality. Notable markers include voltage-gated sodium channels such as Nav1.7, Nav1.8, and Nav1.9, as well as transient receptor potential (TRP) channels TRPV1 and TRPM8. The presence of the purinergic receptor P2RX3 and lineage markers such as PRPH, ISL1, and POU4F1 further validate the sensory identity of these neurons.

The platform also demonstrates the expression of opioid receptors, including OPRM1, OPRK1, and OPRL1, which are critical for analgesic research. Immunocytochemical analysis has shown sustained expression of key proteins such as Brn3a, Peripherin, and Islet 1 over a four-week culture period, confirming both transcriptomic characterization and neuronal maturation.

Dr. Semra Sahin, Applications Scientist at BrainXell, emphasized the complexity of human sensory neuron biology, particularly in the domain of pain signaling and ion channel activity. “Our goal with this platform was to deliver a reproducible human model that combines strong molecular identity with functional responsiveness,” she stated. This advancement aims to enhance the predictive power of data generated in pharmacology and translational neuroscience research.

The development of these sensory neurons addresses some of the limitations seen in traditional sensory neuron models. By integrating controlled differentiation workflows with scalable manufacturing processes, BrainXell ensures stringent quality control. Consistency across production runs is supported by stable quantitative PCR (qPCR) values for sensory neuron markers relative to GAPDH, enabling reliable experimental outcomes.

Functional validation studies indicate that the neurons respond effectively to established sensory agonists and stimuli. This responsiveness opens new avenues for research in nociception, sensory signaling pathways, and ion channel pharmacology, leveraging physiologically relevant human biology.

Researchers interested in the new sensory neurons will have an opportunity for a first look during a presentation scheduled for April 2, 2026, on Scientist.com. Dr. Sahin, along with Business Development Manager Matt Mandeville, will present detailed characterization and functional performance data, showcasing the capabilities of the newly launched product.

BrainXell continues to advance the field of neuroscience by developing and manufacturing human iPSC-derived neural cells, disease models, and assay services designed to improve experimental reproducibility and translational insight across research and drug discovery. As the demand for innovative solutions in neuroscience grows, BrainXell’s latest offering stands out as a significant contribution to the field.